Prof Simon Harrison
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
470 Scholarly works
13 Projects
HIGHLIGHTS
2026
Journal article
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
DOI: 10.1186/s41687-026-01034-z2026
Journal article
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis
DOI: 10.1002/ajh.703762026
Journal article
Cytomegalovirus reactivation in patients with multiple myeloma receiving bispecific antibodies
DOI: 10.1182/bloodadvances.20250195632026
Research grants (international)
Using Novel Biological Therapies to Target a Tumor-Specific Isoform of HER2 for the Treatment of Advanced Breast Cancer.
2021
Research grants (ARC, NHMRC, MRFF)
Studying the Origins, Maintenance and Resistance Mechanisms of Poor Risk Paediatric Leukaemia at Single Cell Resolution to Develop Novel Therapeutic Approaches
2020
Research Grant
ProTreat: An Adaptive and Rapid Implementation Trial of Novel Therapies to Prevent and Treat COVID19 Infection in High Risk Cancer Patients
2017
Journal article
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
DOI: 10.1182/blood-2017-06-788323
RECENT SCHOLARLY WORKS
2026
Journal article
A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma
DOI: 10.1182/blood.20250320442026
Journal article
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort study.
DOI: 10.1016/j.cmi.2026.06.0192026
Journal article
Updated results from inMMyCAR, the ongoing first-in-human phase 1 study of KLN-1010 in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
DOI: 10.1200/jco.2026.44.16_suppl.75092026
Journal article
Infections in the First 30 Days after Chimeric Antigen Receptor T-Cell Therapy in Patients Not Receiving Fluoroquinolone Prophylaxis.
DOI: 10.1016/j.jtct.2026.03.0402026
Journal article
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
DOI: 10.1182/blood.20250323072026
Journal article
A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases.
DOI: 10.1038/s41698-026-01462-62026
Journal article
DEVELOPMENT AND CLINICAL DELIVERY OF AN AUSTRALIAN-MANUFACTURED CD19 CAR-T CELL THERAPY: THE PLATYPS STUDY
DOI: 10.1016/j.jcyt.2026.102647
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
Next Generation Cellular Immunotherapy for Multiple Myeloma and Beyond